{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:58:41Z","timestamp":1789786721393,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T00:00:00Z","timestamp":1475539200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00467-016-3495-1","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T17:12:39Z","timestamp":1475601159000},"page":"321-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Achieving remission of proteinuria in childhood CKD"],"prefix":"10.1007","volume":"32","author":[{"given":"Piero","family":"Ruggenenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cravedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Chianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MariaRosa","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-3446","authenticated-orcid":false,"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,4]]},"reference":[{"key":"3495_CR1","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1681\/ASN.2012040390","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Cravedi P, Remuzzi G (2012) Mechanisms and treatment of CKD. J Am Soc Nephrol 23:1917\u20131928","journal-title":"J Am Soc Nephrol"},{"key":"3495_CR2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/sj.ki.5001729","volume":"70","author":"P Ruggenenti","year":"2006","unstructured":"Ruggenenti P, Remuzzi G (2006) Time to abandon microalbuminuria? Kidney Int 70:1214\u20131222","journal-title":"Kidney Int"},{"key":"3495_CR3","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","volume":"63","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti P, Perna A, Remuzzi G, Investigators GG (2003) Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 63:2254\u20132261","journal-title":"Kidney Int"},{"key":"3495_CR4","doi-asserted-by":"publisher","DOI":"10.1159\/000445844","author":"M Cortinovis","year":"2016","unstructured":"Cortinovis M, Ruggenenti P, Remuzzi G (2016) Progression, remission and regression of chronic renal diseases. Nephron. doi: 10.1159\/000445844","journal-title":"Nephron"},{"key":"3495_CR5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-3476(82)80177-7","volume":"101","author":"GS Arbus","year":"1982","unstructured":"Arbus GS, Poucell S, Bacheyie GS, Baumal R (1982) Focal segmental glomerulosclerosis with idiopathic nephrotic syndrome: three types of clinical response. J Pediatr 101:40\u201345","journal-title":"J Pediatr"},{"key":"3495_CR6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/sj.ki.5000060","volume":"69","author":"A Remuzzi","year":"2006","unstructured":"Remuzzi A, Gagliardini E, Sangalli F, Bonomelli M, Piccinelli M, Benigni A, Remuzzi G (2006) ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 69:1124\u20131130","journal-title":"Kidney Int"},{"key":"3495_CR7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1681\/ASN.2014100971","volume":"27","author":"A Remuzzi","year":"2016","unstructured":"Remuzzi A, Sangalli F, Macconi D, Tomasoni S, Cattaneo I, Rizzo P, Bonandrini B, Bresciani E, Longaretti L, Gagliardini E, Conti S, Benigni A, Remuzzi G (2016) Regression of renal disease by angiotensin II antagonism is caused by regeneration of kidney vasculature. J Am Soc Nephrol 27:699\u2013705","journal-title":"J Am Soc Nephrol"},{"key":"3495_CR8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","volume":"123","author":"JC Peterson","year":"1995","unstructured":"Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL (1995) Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123:754\u2013762","journal-title":"Ann Intern Med"},{"key":"3495_CR9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","volume":"352","author":"P Ruggenenti","year":"1998","unstructured":"Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1252\u20131256","journal-title":"Lancet"},{"key":"3495_CR10","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, Investigators RS (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"3495_CR11","doi-asserted-by":"crossref","unstructured":"(1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349:1857\u20131863","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"3495_CR12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00467-011-1939-1","volume":"27","author":"J Harambat","year":"2012","unstructured":"Harambat J, van Stralen KJ, Kim JJ, Tizard EJ (2012) Epidemiology of chronic kidney disease in children. Pediatr Nephrol 27:363\u2013373","journal-title":"Pediatr Nephrol"},{"key":"3495_CR13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0022-3476(88)80073-8","volume":"112","author":"H Trachtman","year":"1988","unstructured":"Trachtman H, Gauthier B (1988) Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. J Pediatr 112:295\u2013298","journal-title":"J Pediatr"},{"key":"3495_CR14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s004670050373","volume":"11","author":"G Lama","year":"1997","unstructured":"Lama G, Salsano ME, Pedulla M, Grassia C, Ruocco G (1997) Angiotensin converting enzyme inhibitors and reflux nephropathy: 2-year follow-up. Pediatr Nephrol 11:714\u2013718","journal-title":"Pediatr Nephrol"},{"key":"3495_CR15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ki.2012.210","volume":"82","author":"NJ Webb","year":"2012","unstructured":"Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C (2012) Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int 82:819\u2013826","journal-title":"Kidney Int"},{"key":"3495_CR16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00467-012-2372-9","volume":"28","author":"NJ Webb","year":"2013","unstructured":"Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, Lam C (2013) Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome. Pediatr Nephrol 28:737\u2013743","journal-title":"Pediatr Nephrol"},{"key":"3495_CR17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","volume":"361","author":"ET Group","year":"2009","unstructured":"Group ET, Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Moller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639\u20131650","journal-title":"N Engl J Med"},{"key":"3495_CR18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3:486\u2013492","journal-title":"Nat Clin Pract Nephrol"},{"key":"3495_CR19","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","volume":"357","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti P, Schieppati A, Remuzzi G (2001) Progression, remission, regression of chronic renal diseases. Lancet 357:1601\u20131608","journal-title":"Lancet"},{"key":"3495_CR20","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJMe0908183","volume":"361","author":"JR Ingelfinger","year":"2009","unstructured":"Ingelfinger JR (2009) Blood-pressure control and delay in progression of kidney disease in children. N Engl J Med 361:1701\u20131703","journal-title":"N Engl J Med"},{"key":"3495_CR21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1523-1755.2003.00832.x","volume":"63","author":"R Campbell","year":"2003","unstructured":"Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P (2003) Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63:1094\u20131103","journal-title":"Kidney Int"},{"key":"3495_CR22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000045998","volume":"88","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti P, Brenner BM, Remuzzi G (2001) Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron 88:254\u2013259","journal-title":"Nephron"},{"key":"3495_CR23","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","volume":"19","author":"P Ruggenenti","year":"2008","unstructured":"Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G (2008) Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 19:1213\u20131224","journal-title":"J Am Soc Nephrol"},{"key":"3495_CR24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000381480","volume":"130","author":"E Daina","year":"2015","unstructured":"Daina E, Cravedi P, Alpa M, Roccatello D, Gamba S, Perna A, Gaspari F, Remuzzi G, Ruggenenti P (2015) A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study. Nephron 130:13\u201320","journal-title":"Nephron"},{"key":"3495_CR25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5301\/JN.2011.7763","volume":"24","author":"Remission Clinic Task F, Clinical Research Center \"Aldo e Cele D","year":"2011","unstructured":"Remission Clinic Task F, Clinical Research Center \"Aldo e Cele D (2011) The Remission Clinic approach to halt the progression of kidney disease. J Nephrol 24:274\u2013281","journal-title":"J Nephrol"},{"key":"3495_CR26","first-page":"567","volume":"46","author":"M Panteghini","year":"2008","unstructured":"Panteghini M, Division IS (2008) Enzymatic assays for creatinine: time for action. Clin Chem Lab Med 46:567\u2013572","journal-title":"Clin Chem Lab Med"},{"key":"3495_CR27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637","journal-title":"J Am Soc Nephrol"},{"key":"3495_CR28","doi-asserted-by":"crossref","unstructured":"Vidmar SI, Cole TJ, Pan H (2013) Standardizing anthropometric measures in children and adolescents with functions for egen:Update. Stat J 13:366\u2013378","DOI":"10.1177\/1536867X1301300211"},{"key":"3495_CR29","doi-asserted-by":"crossref","unstructured":"Carpenter JR, Goldstein H, Kenward MG (2011) REALCOM-IMPUTE software for multilevel multiple imputation with mixed response types. J Stat Soft 45:1\u201314. URL: http:\/\/www.jstatsoft.org\/v45\/i05\/","DOI":"10.18637\/jss.v045.i05"},{"key":"3495_CR30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.metabol.2005.11.004","volume":"55","author":"J Verbraecken","year":"2006","unstructured":"Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L (2006) Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 55:515\u2013524","journal-title":"Metabolism"},{"key":"3495_CR31","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1681\/ASN.2008040416","volume":"20","author":"E Burgess","year":"2009","unstructured":"Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S, Investigators S (2009) Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 20:893\u2013900","journal-title":"J Am Soc Nephrol"},{"key":"3495_CR32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrneph.2009.77","volume":"5","author":"P Ruggenenti","year":"2009","unstructured":"Ruggenenti P, Cravedi P, Remuzzi G (2009) Proteinuria: Increased angiotensin-receptor blocking is not the first option. Nat Rev Nephrol 5:367\u2013368","journal-title":"Nat Rev Nephrol"},{"key":"3495_CR33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrneph.2012.42","volume":"8","author":"P Cravedi","year":"2012","unstructured":"Cravedi P, Ruggenenti P, Remuzzi G (2012) Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 8:301\u2013306","journal-title":"Nat Rev Nephrol"},{"key":"3495_CR34","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2215\/CJN.04140907","volume":"3","author":"P Ruggenenti","year":"2008","unstructured":"Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G (2008) Angiotensin converting enzyme insertion\/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol 3:1511\u20131525","journal-title":"Clin J Am Soc Nephrol"},{"key":"3495_CR35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"The ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547\u20131559","journal-title":"N Engl J Med"},{"key":"3495_CR36","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrneph.2009.109","volume":"5","author":"P Ruggenenti","year":"2009","unstructured":"Ruggenenti P, Remuzzi G (2009) Proteinuria: Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 5:436\u2013437","journal-title":"Nat Rev Nephrol"},{"key":"3495_CR37","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O\u2019Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369:1892\u20131903","journal-title":"N Engl J Med"},{"key":"3495_CR38","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204\u20132213","journal-title":"N Engl J Med"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-016-3495-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-016-3495-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-016-3495-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T04:01:08Z","timestamp":1568433668000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-016-3495-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["3495"],"URL":"https:\/\/doi.org\/10.1007\/s00467-016-3495-1","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,4]]}}}